Currently, several VEGF-targeting FDA-approved drugs are used as anti-angiogenic cancer treatments, including for gastrointestinal cancer, glioblastoma, non-small lung carcinoma, breast cancer, and renal cancer (17, 18). Here, VEGFA is linked to glioblastoma.